Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
γδ TCR modulator
DRUG CLASS:
γδ TCR modulator
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
ACE2016 (2)
ADI-001 (1)
ACE1831 (0)
ADI-002 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CD7-UCAR-γδT cells (0)
CLN-619 (0)
CTM-N2D (0)
ECT204 (0)
ET 019003 (0)
ET-190 (0)
ET140203 (0)
ET1402L1-ARTEMIS T cells (0)
ET206 (0)
GDT002 (0)
Gamma delta T-cells (0)
ICT01 (0)
INB-100 (0)
INB-200 (0)
INB-300 (0)
autologous γδ T lymphocytes (0)
ALEXIS-ISO-1 (0)
LAVA-051 (0)
LYT-210 (0)
NK/γδ T cell-enriched cell therapy (0)
PF-08046052 (0)
QH104 (0)
TAK-012 (0)
UTAA06 (0)
anti-CD19-CAR γδT (0)
AVM0703 (0)
γδT Cell infusion (0)
γδT Cell infusion agent (0)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
ACE2016 (2)
ADI-001 (1)
ACE1831 (0)
ADI-002 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CD7-UCAR-γδT cells (0)
CLN-619 (0)
CTM-N2D (0)
ECT204 (0)
ET 019003 (0)
ET-190 (0)
ET140203 (0)
ET1402L1-ARTEMIS T cells (0)
ET206 (0)
GDT002 (0)
Gamma delta T-cells (0)
ICT01 (0)
INB-100 (0)
INB-200 (0)
INB-300 (0)
autologous γδ T lymphocytes (0)
ALEXIS-ISO-1 (0)
LAVA-051 (0)
LYT-210 (0)
NK/γδ T cell-enriched cell therapy (0)
PF-08046052 (0)
QH104 (0)
TAK-012 (0)
UTAA06 (0)
anti-CD19-CAR γδT (0)
AVM0703 (0)
γδT Cell infusion (0)
γδT Cell infusion agent (0)
›
Associations
(7)
News
Trials
VERI cancer hierarchy
Reset Filters
CD20 expression
Lymphoma
CD20 expression
Lymphoma
ADI-001
Sensitive: C3 – Early Trials
ADI-001
Sensitive
:
C3
ADI-001
Sensitive: C3 – Early Trials
ADI-001
Sensitive
:
C3
HER-2 positive
Gastrointestinal Stromal Tumor
HER-2 positive
Gastrointestinal Stromal Tumor
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
HER-2 positive
Solid Tumor
HER-2 positive
Solid Tumor
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
EGFR expression
Solid Tumor
EGFR expression
Solid Tumor
ACE2016
Sensitive: D – Preclinical
ACE2016
Sensitive
:
D
ACE2016
Sensitive: D – Preclinical
ACE2016
Sensitive
:
D
EGFR expression
Breast Cancer
EGFR expression
Breast Cancer
ACE2016
Sensitive: D – Preclinical
ACE2016
Sensitive
:
D
ACE2016
Sensitive: D – Preclinical
ACE2016
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login